Ryoncil® Sales Jump 60% to $35.1M; Secures $125M Low-Cost Financing

summarizeSummary

Mesoblast announced a 60% increase in Ryoncil® sales to $35.1 million for the December quarter and secured a new $125 million low-cost financing facility, significantly strengthening its financial position and supporting future growth.

check_boxKey Events

• Strong Ryoncil® Sales Growth

  Gross revenue from Ryoncil® sales increased by 60% quarter-over-quarter to US$35.1 million for the December 2025 quarter.

• New $125M Financing Facility

  Mesoblast secured a new five-year, interest-only facility with its largest shareholder, featuring substantially lower costs, no early repayment fees, no exit fees, and no encumbrance on material assets or intellectual property.

• Balance Sheet Strengthening

  The new facility enabled the full repayment of a prior senior secured loan and partial repayment of a subordinated royalty facility, significantly improving the company's financial flexibility.

• Adult SR-aGvHD Trial Planned

  Ryoncil® will be evaluated in a pivotal trial for adults with steroid-refractory acute graft-versus-host disease (SR-aGvHD), a market approximately three times larger than the current pediatric indication.

auto_awesomeAnalysis

Mesoblast reported robust quarterly sales growth for its FDA-approved Ryoncil®, indicating strong commercial traction. Concurrently, the company secured a substantial $125 million financing facility with highly favorable terms, significantly strengthening its balance sheet and reducing its cost of capital. This dual positive development provides substantial financial flexibility for strategic partnerships and future label expansion initiatives, positioning the company for continued growth.